CE, C., JS, K., J, C., J, F., S, S., JY, C., . . . HC, T. (2024). Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert review of pharmacoeconomics & outcomes research, 24(5), 631. https://doi.org/10.1080/14737167.2024.2319607
Chicago Style (17th ed.) CitationCE, Chee, Khara JS, Cheong J, Fong J, Sivanesan S, Choy JY, Hu M, Viswambaram A, and Toh HC. "Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Compared with Sorafenib as First-line Treatment in Advanced Hepatocellular Carcinoma in Singapore." Expert Review of Pharmacoeconomics & Outcomes Research 24, no. 5 (2024): 631. https://doi.org/10.1080/14737167.2024.2319607.
MLA (9th ed.) CitationCE, Chee, et al. "Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Compared with Sorafenib as First-line Treatment in Advanced Hepatocellular Carcinoma in Singapore." Expert Review of Pharmacoeconomics & Outcomes Research, vol. 24, no. 5, 2024, p. 631, https://doi.org/10.1080/14737167.2024.2319607.
